Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252629 | 0.94 | LPL (0.56) | LPLLIPGPPARGPPARATDP1 | |
| Magnesium Chloride Anhydrous SCHEMBL29043242 | 0.93 | LPL (0.44) | LPLLIPGSKP2NPC1HPGD | |
| SCHEMBL7331955 | 0.92 | LPL (0.57) | LPLLIPGPPARGPPARATDP1 | |
| SCHEMBL9064256 | 0.92 | LPL (0.57) | LPLLIPGPPARGPPARATDP1 | |
| SCHEMBL11650281 | 0.92 | LPL (0.57) | LPLLIPGPPARGPPARATDP1 | |
| SCHEMBL7332490 | 0.92 | LPL (0.57) | LPLLIPGPPARGPPARATDP1 | |
| SCHEMBL9063297 | 0.92 | LPL (0.57) | LPLLIPGPPARGPPARATDP1 | |
| SCHEMBL7337578 | 0.92 | LPL (0.57) | LPLLIPGPPARGPPARATDP1 | |
| SCHEMBL910501 | 0.87 | CNR1 (0.42) | LPLLIPGDRD2OPRM1DRD3 | |
| SCHEMBL347126 | 0.84 | LPL (0.57) | LPLLIPGSKP2NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106588696-B | A kind of preparation method of trans- 'alpha ', ' bela '-unsaturated nitrile class compound | 西北师范大学 | 2018-12-25 | — | — | CN | claimed |
| CN-106588696-A | Preparation method of trans-alpha, beta-unsaturated nitriles compound | 西北师范大学 | 2017-04-26 | — | — | CN | claimed |
| US-6846953-B1 | Aromatic amides | WARNER LAMBERT COMPANY (US) | 2005-01-25 | — | — | US | claimed |
| EP-1178953-B1 | AROMATIC AMIDES | WARNER LAMBERT CO (US) | 2003-12-03 | — | — | EP | claimed |
| US-12012475-B2 | Method of olefin polymerization using alkane-soluble non-metallocene precatalyst | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-06-18 | — | — | US | disclosed |
| CN-112823163-B | Alkane soluble non-metallocene precatalyst | 陶氏环球技术有限责任公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11859031-B2 | Alkane-soluble non-metallocene precatalysts | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3877392-B1 | ALKANE-SOLUBLE NON-METALLOCENE PRECATALYSTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-112839966-B | Process for the polymerization of olefins using an alkane soluble non-metallocene pre-catalyst | 陶氏环球技术有限责任公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20220010045-A1 | ALKANE-SOLUBLE NON-METALLOCENE PRECATALYSTS | DOW GLOBAL TECHNOLOGIES LLC | 2022-01-13 | — | — | US | disclosed |
| US-20210403615-A1 | METHOD OF OLEFIN POLYMERIZATION USING ALKANE-SOLUBLE NON-METALLOCENE PRECATALYST | DOW GLOBAL TECHNOLOGIES LLC | 2021-12-30 | — | — | US | disclosed |
| EP-3877392-A1 | ALKANE-SOLUBLE NON-METALLOCENE PRECATALYSTS | Dow Global Technologies LLC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-4725601-A | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| CN-86104313-A | The preparation method of Imidazoheterocyclic compounds | — | 1987-03-04 | — | — | CN | disclosed |
| EP-0204285-A1 | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
| US-4625009-A | POLYMER OF N,N-DIMETHYLACRYLAMIDE, UNSATURATED CARBOXYLIC ACID, HYDROPHOBIC (METH)ACRYLATE ESTER, POLYALKYLENE GLYCOL DI(METH)ACRYLATE | HOYA CORPORATION (JP) | 1986-11-25 | — | — | US | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859031-B2 | Alkane-soluble non-metallocene precatalysts | AP1M1, CCNA1, AMY1A | LPL 2459/4885LIPG 4106/4885SKP2 154/4885 |
| US-20220010045-A1 | ALKANE-SOLUBLE NON-METALLOCENE PRECATALYSTS | AP1M1, CCNA1, AMY1A | LPL 2459/4885LIPG 4106/4885SKP2 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.